Diagnostics In Brief

Genzyme pharmacogenomics: Firm announces availability of its KRAS gene mutation analysis test to help identify 15%-30% of non-small cell lung cancer tumors unlikely to respond to treatment with drugs Tarceva (Genentech) or Iressa (AstraZeneca). The test, available only through Genzyme's lab, joins two other assays in the firm's portfolio that can conversely detect improved response rates to those drugs based on mutations in the epidermal growth factor receptor gene (1"The Gray Sheet" Oct. 3, 2005, In Brief). "This important convergence of diagnostics and therapeutics is a priority for the company," Genzyme says...